A randomized controlled clinical trial evaluating the immunogenicity of standard-dose, high-dose, MF59-adjuvanted, and recombinant influenza vaccines in the elderly population (65–82 years) showed that enhanced (high-dose and adjuvanted) influenza vaccines increase the polyfunctional CD4+ and CD8+ T-cell response. The gene discussed is CD8A; the disease is influenza.